Share Price:

APNASPENAspen Pharmacare Hldgs164250 (0.00%)
Our Response to Covid
Country Sites

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Tag: Type II diabetes

Aspen announces local availability of Lilly’s Mounjaro

Stephen Saad, Aspen Group Chief Executive

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.

Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day

Heinz Schütte, Aspen Pharmacare Regional CEO, Dr Reyna Daya, SEMDSA President & Endocrinologist, and Stavros Nicolau, Aspen Group Senior Executive Strategic Trade

Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.

Our Purpose

Find out more
To improve the health and quality of life of patients.

Our Vision

Find out more
To deliver value to all our stakeholders as a responsible corporate citizen that provides high-quality, affordable medicines globally.

Our Values

Find out more
Define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group.
aspen-holdings-logo-white-img

Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912

Medical Careline (South Africa) 0800 118 088

Facebook-f Twitter-square Instagram Linkedin

About Aspen

We Care

Careers

Contact Us

ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600

Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.